Last reviewed · How we verify

KIMJisun — Portfolio Competitive Intelligence Brief

KIMJisun pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Melatonin(Circadin®) Melatonin(Circadin®) marketed Melatonin receptor agonist MT1 and MT2 melatonin receptors Neurology / Sleep Medicine

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Ain Shams University · 1 shared drug class
  2. Al-Azhar University · 1 shared drug class
  3. Azienda Ospedaliera Universitaria Policlinico "G. Martino" · 1 shared drug class
  4. B.P. Koirala Institute of Health Sciences · 1 shared drug class
  5. Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health · 1 shared drug class
  6. Hospital San Carlos, Madrid · 1 shared drug class
  7. Imperial College London · 1 shared drug class
  8. Rush University Medical Center · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for KIMJisun:

Cite this brief

Drug Landscape (2026). KIMJisun — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/kimjisun. Accessed 2026-05-14.

Related